AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25784955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (exclusive breastfeeding promotion by peer counsellors)
Number of subjects: 2579
Study 25784955 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 2579
Study 25785226 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary polyunsaturated fatty acids (PUFAs) intake
Number of subjects: 266
Study 25785226 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary polyunsaturated fatty acids (PUFAs) intake in hormone therapy (HT) group
Number of subjects: 266
Study 25785226 — intervention group
Group type: COMPARATOR
Intervention: Dietary polyunsaturated fatty acids (PUFAs) intake in non-hormone therapy (non-HT) group
Number of subjects: 266
Study 25785487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum oxytocin
Number of subjects: 98
Study 25785487 — intervention group
Group type: COMPARATOR
Intervention: Control (no intrapartum oxytocin)
Number of subjects: 98
Study 25785995 — intervention group
Group type: EXPERIMENTAL
Intervention: pH1N1 vaccine (two double doses)
Number of subjects: 90
Study 25786035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists (MRAs), n=101
Number of subjects: 427
Study 25786035 — intervention group
Group type: COMPARATOR
Intervention: No mineralocorticoid receptor antagonists (MRA-Neg), n=101
Number of subjects: 427
Study 25786047 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy programme (16 weeks)
Number of subjects: 20
Study 25786047 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 20
Study 25786252 — intervention group
Group type: EXPERIMENTAL
Intervention: High IGF1R gene expression
Number of subjects: 217
Study 25786252 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IGF1R expression
Number of subjects: 217
Study 25786252 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF1R expression
Number of subjects: 217
Study 25786708 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular-targeted photodynamic therapy with TOOKAD(®) Soluble
Number of subjects: 0
Study 25787057 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT adherence measured by medication possession ratio (MPR) >0.9
Number of subjects: 3151
Study 25787057 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT adherence measured by medication possession ratio (MPR) >0.5-<0.9
Number of subjects: 3151
Study 25787057 — intervention group
Group type: COMPARATOR
Intervention: DMT adherence measured by medication possession ratio (MPR) <0.5
Number of subjects: 3151
Study 25787923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 6, 8, or 10 mg/kg Q2W
Number of subjects: 25
Study 25787923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 15 or 20 mg/kg Q3W
Number of subjects: 25
Study 25787923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (all doses)
Number of subjects: 25
Study 25787996 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidic acid (20:0) in the highest quartile
Number of subjects: 3179
Study 25787996 — intervention group
Group type: EXPERIMENTAL
Intervention: Behenic acid (22:0) in the highest quartile
Number of subjects: 3179
Study 25787996 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignoceric acid (24:0) in the highest quartile
Number of subjects: 3179
Study 25787996 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidic acid (20:0) after adjustment for triglycerides and palmitic acid
Number of subjects: 3179
Study 25788178 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with concomitant thalidomide
Number of subjects: 43
Study 25788178 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 43
Study 25788458 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 4086
Study 25788949 — intervention group
Group type: EXPERIMENTAL
Intervention: ragweed SLIT-T 6 Amb a 1-U
Number of subjects: 337
Study 25788949 — intervention group
Group type: EXPERIMENTAL
Intervention: ragweed SLIT-T 12 Amb a 1-U
Number of subjects: 337
Study 25788949 — intervention group
Group type: EXPERIMENTAL
Intervention: ragweed SLIT-T
Number of subjects: 337
Study 25789557 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 34
Study 25789557 — intervention group
Group type: COMPARATOR
Intervention: Micropore tape (Control)
Number of subjects: 34
Study 25789614 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperpnea (EVH)
Number of subjects: 52
Study 25789614 — intervention group
Group type: COMPARATOR
Intervention: Methacholine inhalation test (MIT)
Number of subjects: 52
Study 25789989 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE treatment) administered for 12 weeks
Number of subjects: 15
Study 25790480 — intervention group
Group type: EXPERIMENTAL
Intervention: PRODIGI (autofluorescence imaging device)
Number of subjects: 40
Study 25790767 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25790876 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid plaque burden (cPB)
Number of subjects: 5808
Study 25790876 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcification (CAC)
Number of subjects: 5808
Study 25790876 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of major adverse cardiac events (MACE)
Number of subjects: 5808
Study 25790876 — intervention group
Group type: EXPERIMENTAL
Intervention: cPB and CAC
Number of subjects: 5808
Study 25792386 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 167
Study 25792386 — intervention group
Group type: EXPERIMENTAL
Intervention: CEH-EUS
Number of subjects: 167
Study 25792386 — intervention group
Group type: EXPERIMENTAL
Intervention: ANN
Number of subjects: 167
Study 25793018 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal venous pressure (RVP) measurement in patients with diabetic retinopathy (DR)
Number of subjects: 0
Study 25793018 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal venous pressure (RVP) measurement in patients without diabetic retinopathy (nonDR)
Number of subjects: 0
Study 25793018 — intervention group
Group type: COMPARATOR
Intervention: Retinal venous pressure (RVP) measurement in healthy control subjects
Number of subjects: 0
Study 25793152 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg weekly for 12 weeks
Number of subjects: 210
Study 25793152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 25793933 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine and albendazole (DEC/Alb) - single dose
Number of subjects: 79
Study 25793960 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated Flolan (epoprostenol sodium)
Number of subjects: 16
Study 25793960 — intervention group
Group type: COMPARATOR
Intervention: Currently marketed Flolan (epoprostenol sodium)
Number of subjects: 16
Study 25794066 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX-B (gemcitabine and oxaliplatin combined with bevacizumab)
Number of subjects: 28
Study 25794243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Insulin Titration Intervention (MITI) - texting/phone call intervention
Number of subjects: 0
Study 25794243 — intervention group
Group type: COMPARATOR
Intervention: Usual-care arm - in-person clinic visits
Number of subjects: 0
Study 25794535 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib plus cisplatin (100 mg/m(2))
Number of subjects: 61
Study 25794535 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib plus carboplatin (AUC6)
Number of subjects: 61
Study 25795132 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-mediated cytotoxic immunotherapy (GMCI) with AdV-tk + prodrug in Arm A
Number of subjects: 24
Study 25795132 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-mediated cytotoxic immunotherapy (GMCI) with AdV-tk + prodrug in Arm B
Number of subjects: 24
Study 25795132 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment in both arms
Number of subjects: 24
Study 25795402 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m²) followed by Trabectedin (1.1 mg/m²) and Pegfilgrastim (6 mg) every 3 weeks for up to six cycles
Number of subjects: 109
Study 25795432 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0
Study 25795432 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 0
Study 25795432 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 0
Study 25795637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 100-450 mg once daily (n = 40)
Number of subjects: 51
Study 25795637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 250 mg b.i.d. (n = 11)
Number of subjects: 51
Study 25795637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (various doses)
Number of subjects: 51
Study 25795637 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose (MTD)
Number of subjects: 51
Study 25795722 — intervention group
Group type: EXPERIMENTAL
Intervention: Resimmune (2.5 - 11.25 μg/kg intravenous infusion over 15 minutes)
Number of subjects: 30
Study 25795794 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta (1 mg/kg/2 weeks)
Number of subjects: 52
Study 25795917 — intervention group
Group type: EXPERIMENTAL
Intervention: GSDI (Glaucoma Structural Diagnostic Index) using NFL, GCC, and disc variables
Number of subjects: 166
Study 25795917 — intervention group
Group type: EXPERIMENTAL
Intervention: GSDI
Number of subjects: 166
Study 25798215 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplements (1.5 g)
Number of subjects: 38
Study 25798215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 25798374 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week group-based intervention
Number of subjects: 68
Study 25798374 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 68
Study 25798999 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C-MRB PET-CT imaging under room temperature (RT) conditions
Number of subjects: 10
Study 25798999 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C-MRB PET-CT imaging under cold-stimulated conditions
Number of subjects: 10
Study 25798999 — intervention group
Group type: COMPARATOR
Intervention: (18)F-FDG PET-CT imaging
Number of subjects: 10
Study 25800136 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome group (MetS)
Number of subjects: 599
Study 25800136 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MetS)
Number of subjects: 599
Study 25800136 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glomerular filtration rate < 30 mL/min
Number of subjects: 599
Study 25800136 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 599
Study 25800136 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel intervention
Number of subjects: 599
Study 25800136 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 599
Study 25800893 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease levels <1% on day 19
Number of subjects: 498
Study 25800893 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease levels ≥1% on day 19
Number of subjects: 498
Study 25800893 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative minimal residual disease (<0.01%) on day 46 after ≥1% on day 19
Number of subjects: 498
Study 25800893 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent minimal residual disease on day 46 for standard-risk patients
Number of subjects: 498
Study 25800893 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing minimal residual disease levels between end of induction and week 7 of maintenance therapy
Number of subjects: 498
Study 25800893 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease re-emergence
Number of subjects: 498
Study 25801562 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy including telaprevir
Number of subjects: 27
Study 25801562 — intervention group
Group type: COMPARATOR
Intervention: After telaprevir withdrawal
Number of subjects: 27
Study 25801562 — intervention group
Group type: COMPARATOR
Intervention: PegIFN-α plus ribavirin
Number of subjects: 27
Study 25801567 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate 300 mg once daily
Number of subjects: 150
Study 25801567 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC4 4131 TG or GG genotype
Number of subjects: 150
Study 25801567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low body weight, low eGFR, concomitant use of ritonavir-boosted protease inhibitors
Number of subjects: 150
Study 25801692 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (T&A)
Number of subjects: 100
Study 25801710 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilator stress cardiac MRI
Number of subjects: 139
Study 25801710 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic reference subjects
Number of subjects: 139
Study 25802238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 61
Study 25802729 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg canagliflozin
Number of subjects: 0
Study 25802729 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg canagliflozin
Number of subjects: 0
Study 25802729 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet/exercise alone or diet/exercise plus oral antihyperglycemic drug)
Number of subjects: 0
Study 25802843 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic profiling using umbilical cord blood samples
Number of subjects: 0
Study 25802843 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised multicentre recruitment
Number of subjects: 0
Study 25802843 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive biospecimen collection
Number of subjects: 0
Study 25802843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pristine biobanking and phenotyping
Number of subjects: 0
Study 25802932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg/m² weekly for 4 weeks, then concurrent with gemcitabine (800 mg/m²) or cisplatin (50 mg/m²) for 18 weeks, then maintenance every 2 weeks)
Number of subjects: 17
Study 25802932 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent phase with chemotherapy (gemcitabine or cisplatin)
Number of subjects: 17
Study 25802932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab (single agent during induction and maintenance phases)
Number of subjects: 17
Study 25803093 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg + Rifampin 600 mg
Number of subjects: 24
Study 25803093 — intervention group
Group type: COMPARATOR
Intervention: Bosutinib alone
Number of subjects: 24
Study 25803093 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib + Rifampin
Number of subjects: 24
Study 25803140 — intervention group
Group type: EXPERIMENTAL
Intervention: Exaggerated HPV subjects (n=33) ascended to 4559m, 4 (13%) developed HAPE during the 48h stay.
Number of subjects: 421
Study 25803140 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n=unknown)
Number of subjects: 421
Study 25803226 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile telehealth (MTH) intervention
Number of subjects: 86
Study 25803226 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 86
Study 25803243 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with bronchoalveolar lavage (BAL)
Number of subjects: 15
Study 25803243 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with protected-specimen brush
Number of subjects: 15
Study 25803243 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of microbiota from spatially separated intrapulmonary sites
Number of subjects: 15
Study 25803243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasubject variation
Number of subjects: 15
Study 25803243 — intervention group
Group type: EXPERIMENTAL
Intervention: Right upper lobe microbiota
Number of subjects: 15
Study 25803243 — intervention group
Group type: EXPERIMENTAL
Intervention: Community richness
Number of subjects: 15
Study 25803268 — intervention group
Group type: EXPERIMENTAL
Intervention: Histrelin subcutaneous implant
Number of subjects: 36
Study 25804349 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular pacing (%RVP)
Number of subjects: 1395
Study 25804569 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electrocardiographic monitoring of heart rate (HR) during the first 72 hours after admission.
Number of subjects: 702
Study 25804569 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of HR during the first 12 hours after admission.
Number of subjects: 702
Study 25804941 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 20
Study 25804941 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 20
Study 25804941 — intervention group
Group type: COMPARATOR
Intervention: G-CSF with/without chemotherapy
Number of subjects: 20
Study 25804941 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF plus plerixafor
Number of subjects: 20
Study 25804941 — intervention group
Group type: COMPARATOR
Intervention: G-CSF without plerixafor
Number of subjects: 20
Study 25805158 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of bleeding avoidance strategies (bivalirudin, radial approach, vascular closure devices)
Number of subjects: 10937
Study 25805158 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding rates within intervention sites
Number of subjects: 10937
Study 25805158 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in use of bleeding avoidance strategies
Number of subjects: 10937
Study 25805361 — intervention group
Group type: EXPERIMENTAL
Intervention: Adeno-tonsillectomy (AT)
Number of subjects: 144
Study 25805361 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 144
Study 25805361 — intervention group
Group type: COMPARATOR
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 144
Study 25806103 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted ketogenic diet (ERKD)
Number of subjects: 32
Study 25806103 — intervention group
Group type: COMPARATOR
Intervention: Ketogenic diet (KD)
Number of subjects: 32
Study 25806231 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized chemotherapy
Number of subjects: 0
Study 25806231 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/gemcitabine
Number of subjects: 0
Study 25806231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/docetaxel or docetaxel alone
Number of subjects: 0
Study 25806231 — intervention group
Group type: COMPARATOR
Intervention: Non-customized cisplatin/docetaxel
Number of subjects: 0
Study 25806291 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib treatment with low/intermediate ROR1 levels
Number of subjects: 45
Study 25806291 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib treatment with high ROR1 levels
Number of subjects: 45
Study 25806291 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment with low/intermediate ROR1 levels
Number of subjects: 45
Study 25806291 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment with high ROR1 levels
Number of subjects: 45
Study 25806291 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib treatment with T790M mutation and low/intermediate ROR1 levels
Number of subjects: 45
Study 25806291 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib treatment with T790M mutation and high ROR1 levels
Number of subjects: 45
Study 25806291 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment with T790M mutation and low/intermediate ROR1 levels
Number of subjects: 45
Study 25806291 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment with T790M mutation and high ROR1 levels
Number of subjects: 45
Study 25806824 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness (measured by VO2 peak)
Number of subjects: 273
Study 25806824 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient status adjustment
Number of subjects: 273
Study 25807199 — intervention group
Group type: EXPERIMENTAL
Intervention: FMSA
Number of subjects: 25
Study 25807199 — intervention group
Group type: COMPARATOR
Intervention: CellSearch®
Number of subjects: 25
Study 25807932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (0.1 mg/kg/day)
Number of subjects: 22
Study 25809054 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessments, clinical and diagnostic information, biological and molecular markers.
Number of subjects: 3479
Study 25809054 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional and clinical parameters recorded before, during hospital admission and at discharge.
Number of subjects: 3479
Study 25809354 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoAnchors
Number of subjects: 208
Study 25809731 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP-AUY922 monotherapy
Number of subjects: 29
Study 25809731 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP-AUY922 plus bortezomib
Number of subjects: 29
Study 25809824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m² every 3 weeks plus daily prednisolone)
Number of subjects: 44
Study 25810005 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-assessed FN risk
Number of subjects: 944
Study 25810005 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-predicted FN risk
Number of subjects: 944
Study 25810005 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF primary prophylaxis orders
Number of subjects: 944
Study 25810005 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF orders relative to physician's FN risk intervention threshold
Number of subjects: 944
Study 25811755 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse CSHQ score (Children's Sleep Habits Questionnaire)
Number of subjects: 1970
Study 25811755 — intervention group
Group type: EXPERIMENTAL
Intervention: More night-time sleep
Number of subjects: 1970
Study 25811755 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 1970
Study 25811755 — intervention group
Group type: EXPERIMENTAL
Intervention: Time outdoors
Number of subjects: 1970